Ebola outbreak: Domain investor sells Ebola.com for $200,000

Businessman Jon Schultz buys and sells domain names for a profit, including Ebola.com for which he received $50,000 in cash and 19,000 shares in Cannabis Sativa Inc

An internet entrepreneur has sold Ebola.com for $200,000 after buying it in 2008 for $13,500
An internet entrepreneur has sold Ebola.com for $200,000 after buying it in 2008 for $13,500

An internet real estate entrepreneur, who held on to Ebola.com for six years, has reportedly sold it for $200,000 (£124,000).

Jon Schultz’s Blue String Ventures capitalises on the popularity and demand of high profile domain names – investing in them to sell on at a later date at a higher price.

Blue String Ventures bought Ebola.com in 2008 for $13,500 and earlier this month Mr Schultz, who also owns birdflu.com and H1N1.com (Swine Flu), had claimed that a “reasonable” offer would be around the $150,000 mark, considering the website is bringing in 5,000 page views each day.

In an interview with the Washington Post he explained that his business is largely a waiting game and that the deadlier an epidemic is in the West, the more bucks it could rake in: “Our domain birdflu.com is worth way more than Ebola.com. We’re definitely holding onto that one for the event.

“That one’s airborne and Ebola would never go airborne in the United States like bird flu can.”

Days later on 20 October, he agreed to sell Ebola.com to Weed Growth Fund Inc for $50,000 in cash and 19,192 shares of the common stock of Cannabis Sativa Inc (CBDS), according to a Securities and Exchange Commission filing cited by DomainInvesting.

Shares for CBDS on the NASDAQ on Sunday morning currently stand at $9.20 each, valuing that part of the agreement at $176,566 (£109,700).

“We've had others like LasVegasRealEstate.com and PaydayLoans.com that sold for more,” Mr Schultz told HuffingtonPost. “People don't understand what we do. We don't buy domain names hoping there's a disaster.”

Ebola.com

What Weed Growth Fund Inc would want with Ebola.com is anyone’s guess, though as reported by DomainInvesting, the CEO of Cannabis Sativa Inc, Gary Johnson, earlier this month spoke on Fox News about using marijuana to help treat Ebola.

Ebola.com has been updated until 16 October with news articles relating to the outbreak, while visitors can donate to Doctors Without Borders or read about tips to protect oneself from the disease.

Nearly 5,000 people have been killed by Ebola, with most of those in the worst hit countries of Guinea, Sierra Leone and Liberia in West Africa, while the number of cases as surpassed the 10,000 mark.

Blue String Ventures has been contacted by The Independent for comment.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in